Drug
ESG206
ESG206 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
3
75%
Ph phase_2
1
25%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(1)
Terminated(1)
Detailed Status
Recruiting1
Withdrawn1
Completed1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
recruiting125%
withdrawn125%
completed125%
not_yet_recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
not_yet_recruitingphase_2
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome
NCT07375524
withdrawnphase_1
A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies
NCT05263739
completedphase_1
A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies
NCT05822843
recruitingphase_1
A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia
NCT06853444
Clinical Trials (4)
Showing 4 of 4 trials
NCT07375524Phase 2
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome
NCT05263739Phase 1
A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies
NCT05822843Phase 1
A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies
NCT06853444Phase 1
A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4